The FDA is announcing the availability of a draft guidance for industry entitled "Complementary and Alternative Medicine [CAM] Products and Their Regulation by the FDA." The draft guidance discusses when a CAM product is subject to the Federal Food, Drug, and Cosmetic Act or Public Health Service Act. Electronic comments may be submitted by April 30 to
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.